PSNL.US Personalis Inc

Healthcare Life Sciences Tools & Services USA Stocks
14.80 USD
Close of Nov 18, 2026
4.96 18.89
Market cap
USD 1.60B
P/E
-
P/B
7.54x
ROE
-59.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PSNL.US undervalued?

Graham number

The Graham number of Personalis Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Personalis Inc fundamental analysis

No fundamental analysis for Personalis Inc yet.

Personalis Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Personalis Inc

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional…

Full company profile